M D Prados

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Int J Radiat Oncol Biol Phys 49:71-7. 2001
  2. pmc A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma
    Michael D Prados
    Department of Neurological Surgery, University of California San Francisco, 94143, USA
    Neuro Oncol 5:96-103. 2003
  3. pmc Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Michael Prados
    Department of Neurosurgery, University of California San Francisco, 400 Parnassus Ave, A 808, San Francisco, CA 94143, USA
    Neuro Oncol 13:143-51. 2011
  4. pmc Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
  5. ncbi Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial
    Michael D Prados
    University of California, San Francisco, USA
    J Neurooncol 65:269-78. 2003
  6. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
  7. ncbi Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 58:1147-52. 2004
  8. pmc Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
  9. pmc Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Ave, Room 808, San Francisco, CA 94143 0372, USA
    Cancer Chemother Pharmacol 61:1059-67. 2008
  10. pmc Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
    Neuro Oncol 8:67-78. 2006

Research Grants

Detail Information

Publications77

  1. ncbi Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Int J Radiat Oncol Biol Phys 49:71-7. 2001
    ....
  2. pmc A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma
    Michael D Prados
    Department of Neurological Surgery, University of California San Francisco, 94143, USA
    Neuro Oncol 5:96-103. 2003
    ..Recent preclinical pharmacokinetic modeling of RMP-7 suggests that higher doses of RMP-7 may be required to increase carboplatin delivery to tumor...
  3. pmc Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Michael Prados
    Department of Neurosurgery, University of California San Francisco, 400 Parnassus Ave, A 808, San Francisco, CA 94143, USA
    Neuro Oncol 13:143-51. 2011
    ..Clarifying the relationship of OR and survival is important for determining whether OR can be a reliable predictor of the benefit of a therapeutic agent in patients with recurrent GBM...
  4. pmc Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
    ..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response...
  5. ncbi Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial
    Michael D Prados
    University of California, San Francisco, USA
    J Neurooncol 65:269-78. 2003
    ..This treatment modality is feasible and appears to have some evidence of efficacy. Toxicity may be related in part to the method of gene delivery...
  6. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  7. ncbi Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 58:1147-52. 2004
    ....
  8. pmc Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  9. pmc Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Ave, Room 808, San Francisco, CA 94143 0372, USA
    Cancer Chemother Pharmacol 61:1059-67. 2008
    ..The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide...
  10. pmc Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
    Neuro Oncol 8:67-78. 2006
    ..There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted...
  11. pmc A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
    ..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population...
  12. ncbi Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy
    M D Prados
    Department of Neurosurgery, University of California, San Francisco, USA
    Pediatr Neurosurg 25:174-81. 1996
    ....
  13. ncbi Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    Department of Neurosurgery, University of California, San Francisco, USA
    J Clin Oncol 16:2188-94. 1998
    ..To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma...
  14. ncbi Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    J Clin Oncol 17:3389-95. 1999
    ..To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy...
  15. ncbi Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report
    S M Chang
    University of California Medical Center, San Francisco, USA
    J Clin Oncol 17:984-90. 1999
    ..To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent...
  16. ncbi A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404
    M D Prados
    University of California San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 45:1109-15. 1999
    ....
  17. ncbi Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  18. ncbi EGFR overexpression and radiation response in glioblastoma multiforme
    F G Barker
    Department of Neurological Surgery, Neuro Oncology Service and Brain Tumor Research Center, University of California, San Francisco, California, USA
    Int J Radiat Oncol Biol Phys 51:410-8. 2001
    ..We tested whether these abnormalities correlated with clinical heterogeneity in GM response to radiation treatment...
  19. ncbi Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen
    M D Prados
    Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    J Neurooncol 32:235-41. 1997
    ..This regimen was safe, able to be delivered in the outpatient setting, and produced prolonged periods of disease stabilization in children with low-grade gliomas...
  20. ncbi Age and radiation response in glioblastoma multiforme
    F G Barker
    Neuro Oncology Service, Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, USA
    Neurosurgery 49:1288-97; discussion 1297-8. 2001
    ..Radiographically assessed tumor response to external beam radiation therapy is an important prognostic factor in GM. We hypothesized that older GM patients might have more radioresistant tumors...
  21. ncbi A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report
    S M Chang
    Department of Neurosurgery, University of California Medical Center, San Francisco, California, USA
    Cancer 91:417-22. 2001
    ..Secondary objectives were to determine the time period to treatment failure, to evaluate toxicities, and to obtain pharmacokinetic data...
  22. ncbi A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 61:1454-9. 2005
    ....
  23. ncbi Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
    P K Sneed
    Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 40:287-95. 1998
    ..To determine if adjuvant interstitial hyperthermia (HT) significantly improves survival of patients with glioblastoma undergoing brachytherapy boost after conventional radiotherapy...
  24. ncbi Chemotherapy of brain tumors
    M D Prados
    Department of Neurosurgery, University of California, San Francisco 94117, USA
    Semin Surg Oncol 14:88-95. 1998
    ..As part of a multimodality approach that includes surgery and radiotherapy, chemotherapy has a significant role to play in the treatment of both adults and children with brain neoplasms...
  25. ncbi Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:353-7. 2004
    ....
  26. doi Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients
    Seunggu J Han
    Department of Neurological Surgery, University of California, San Francisco, CA, USA
    Cancer 116:1358-66. 2010
    ..In the current study, the authors present a modern series of confirmed PGS cases treated in the era of magnetic resonance imaging (MRI), after the accepted glioblastoma management of resection, radiation, and temozolomide...
  27. ncbi Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme
    Allen M Chen
    Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 69:825-30. 2007
    ..To evaluate the feasibility of gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy for patients with newly diagnosed glioblastoma...
  28. ncbi Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group
    Sandeep Kunwar
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143 0350, USA
    J Clin Oncol 25:837-44. 2007
    ..We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG)...
  29. ncbi Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies
    Sandeep Kunwar
    Department of Neurosurgery, University of California, San Francisco, California 94143 0350, USA
    Neurosurg Focus 20:E15. 2006
    ..Cintredekin besudotox (also known as IL13- PE38QQR) is a recombinant chimeric cytotoxin consisting of interleukin-13 and a truncated exotoxin produced by the Pseudomonas aeruginosa bacterium, which targets malignant glioma cells...
  30. ncbi Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival
    Margaret Wrensch
    Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94102, USA
    Cancer Res 66:4531-41. 2006
    ..3 region influence survival. We also suggest that tumor EGFR expression be incorporated into clinical evaluation of anaplastic astrocytoma patients...
  31. pmc The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas
    Kavita K Mishra
    Brain Tumor Research Center and Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 8:166-74. 2006
    ..We were unable to demonstrate a benefit for administering radiation as part of initial treatment. An outcome benefit was seen with greater extent of resection...
  32. ncbi Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    J Neurooncol 85:87-94. 2007
    ..Patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR...
  33. pmc DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression
    Shichun Zheng
    Department of Neurological Surgery, University of California San Francisco, Helen Diller Family Cancer Center, 1450 3rd Street, San Francisco, CA 94158, USA
    Neuro Oncol 13:280-9. 2011
    ..DNA methylation markers are useful in characterizing distinct glioma subtypes and may hold promise for clinical applications...
  34. doi Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Edward F Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
    J Neurosurg 109:817-24. 2008
    ..As a result, the objective in the present study was to design a preoperative scoring system to prognosticate long-term outcomes in patients with LGGs...
  35. pmc A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:183-9. 2009
    ..Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide...
  36. pmc Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Gautam Prasad
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 13:384-92. 2011
    ..05) with a trend toward improvement in median survival (logrank p = 0.09) compared with TMZ alone. XL765 shows activity as monotherapy and in combination with conventional therapeutics in a range of genetically diverse GBM xenografts...
  37. pmc Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    Neuro Oncol 10:631-42. 2008
    ..It would also include a combined phase 0/I pharmacokinetic study to determine the safety and biologically optimal dose of the agent and to verify successful modulation of the target prior to initiating a larger, phase II efficacy study...
  38. doi Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors
    Sean M McBride
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA
    Int J Radiat Oncol Biol Phys 72:1319-23. 2008
    ..To review a historical cohort of pediatric patients with supratentorial primitive neuroectodermal tumors (sPNET), to clarify the role of radiation in the treatment of these tumors...
  39. pmc Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
    Daphne A Haas-Kogan
    University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 10:341-7. 2008
    ..The MTD of tipifarnib with concurrent radiation is 125 mg/m(2)/dose b.i.d. One-year survival and progression-free survival estimates are 36.4% (SE 16.7%) and 9.4% (SE 6.3%), respectively...
  40. doi A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:175-82. 2009
    ....
  41. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  42. pmc Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 12:608-13. 2010
    ..The proceeding phase II trial has finished accrual and results will be reported in 2009...
  43. pmc Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area
    Margaret Wrensch
    Department of Neurological Surgery, University of California, San Francisco, 44 Page Street Suite 503, San Francisco, CA 94102 1215, USA
    Neuro Oncol 8:12-26. 2006
    ..Further consideration of impact of marital status, education, and other social factors in glioma survival may be warranted...
  44. ncbi Radiation therapy for intracranial germ cell tumors
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 56:511-8. 2003
    ....
  45. ncbi A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report
    Susan M Chang
    University of California Medical Center, San Francisco, CA 94143, USA
    Invest New Drugs 21:429-33. 2003
    ..To compare two different infusion schedules of phenylacetate (PA) in patients with primary brain tumors and to assess the feasibility of the administration in a multi-institutional setting...
  46. ncbi Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
    G Evren Keles
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
    J Neurosurg 100:41-6. 2004
    ..To accomplish this, the authors evaluated a homogeneous group of patients with recurrent GBMs who received the same chemotherapeutic agent...
  47. ncbi Temozolomide in the treatment of recurrent malignant glioma
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 100:605-11. 2004
    ..The authors describe the efficacy and safety results of their institution's open-label, compassionate-use protocol of temozolomide for patients with recurrent malignant glioma...
  48. ncbi Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
    ..The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG...
  49. pmc Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
    David A Larson
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:119-26. 2004
    ..We conclude that permanent 125I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy...
  50. pmc Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0112, USA
    Neuro Oncol 6:227-35. 2004
    ....
  51. ncbi Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M Chang
    Neuro Oncology Service, University of California, San Francisco, CA 94143, USA
    Invest New Drugs 22:427-35. 2004
    ..The objectives of this study were to determine the pharmacokinetic profile and the maximum tolerated dose of CCI-779 in patients with recurrent malignant gliioma taking EIAEDs...
  52. ncbi Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults
    Andrew T Parsa
    Department of Neurological Surgery, School of Medicine, University of California at San Francisco, California 94143, USA
    J Neurosurg 102:622-8. 2005
    ..The objective in the present study was to assess the prognostic significance of disseminated intracranial GBM in adults at presentation and at the time of tumor progression...
  53. ncbi Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
    Daphne A Haas-Kogan
    Department of Neurosurgery, Brain Tumor Research Center, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143, USA
    J Natl Cancer Inst 97:880-7. 2005
    ....
  54. pmc Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas
    Daphne A Haas-Kogan
    University of California San Francisco, San Francisco, CA, USA
    Neuro Oncol 13:298-306. 2011
    ..Biopsies and molecular analyses of pediatric BSGs are vital for identification of new agents and for rational use of targeted agents...
  55. ncbi Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M Chang
    University of California, San Francisco, San Francisco, CA 94143, USA
    Invest New Drugs 23:357-61. 2005
    ..CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug...
  56. ncbi Biomarkers to predict response to epidermal growth factor receptor inhibitors
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California San Francisco, USA
    Cell Cycle 4:1369-72. 2005
    ..Ultimately the goal of these studies is to allow selection of patients who will preferentially respond to EGFR inhibitors...
  57. ncbi Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery
    E E Graves
    Departments of Radiology, University of California, San Francisco 94143, USA
    AJNR Am J Neuroradiol 22:613-24. 2001
    ..Evaluation of metabolic changes with proton MR spectroscopy and structural changes with MR imaging improved tissue discrimination and provided correlation with histologic findings...
  58. pmc p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts
    Eduard B Dinca
    Brain Tumor Research Center, University of California San Francisco, San Francisco, California 94143, USA
    Cancer Res 68:10034-9. 2008
    ..In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner...
  59. ncbi Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results
    Frederick F Lang
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 21:2508-18. 2003
    ..Advances in brain tumor biology indicate that transfer of p53 is an alternative therapy for human gliomas. Consequently, we undertook a phase I clinical trial of p53 gene therapy using an adenovirus vector (Ad-p53, INGN 201)...
  60. pmc Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University ofCalifornia, San Diego, CA, USA
    Neuro Oncol 12:366-76. 2010
    ....
  61. pmc A human brainstem glioma xenograft model enabled for bioluminescence imaging
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, 505 Parnassus Ave, Room M779, San Francisco, CA 94143 0112, USA
    J Neurooncol 96:151-9. 2010
    ..This model is well suited for pre-clinical testing of therapeutics that are being considered for treatment of patients with brainstem tumors...
  62. ncbi Late radiation injury following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumor
    C Russo
    Brain Tumor Research Center of the Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    Int J Radiat Oncol Biol Phys 44:85-90. 1999
    ..To document the late radiographic change following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumor...
  63. ncbi Repeated operations for infiltrative low-grade gliomas without intervening therapy
    Meic H Schmidt
    Department of Neurological Surgery, University of California at San Francisco, California, USA
    J Neurosurg 98:1165-9. 2003
    ..The authors examined factors that may be associated with tumor progression...
  64. doi Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, 505 Parnassus Ave, Room M 779, San Francisco, CA 94143 0112, USA
    J Clin Oncol 26:1338-45. 2008
    ..The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a retrospective study to assess the influence of EOR on long-term outcomes of LGGs...
  65. pmc High failure rate in spinal ependymomas with long-term follow-up
    Daniel R Gomez
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:254-9. 2005
    ..The overall high rate of recurrence leads us to recommend radiation to doses of 45 to 54 Gy for all patients who do not have gross total resections, and long, close follow-up...
  66. pmc Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts
    Karine Michaud
    Department of Neurological Surgery, Helen Diller Comprehensive Cancer Center, University of California San Francisco, California 94143 0520, USA
    Cancer Res 70:3228-38. 2010
    ..In total, our results support clinical trial evaluation of PD-0332991 against newly diagnosed as well as recurrent GBM, and indicate that Rb status is the primary determinant of potential benefit from this therapy...
  67. pmc Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity
    Seunggu J Han
    Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Ave, San Francisco, CA 94117, USA
    J Neurooncol 96:313-20. 2010
    ..Clinical and pathologic characteristics distinct from GBM suggest that they may warrant specific treatment, separate from conventional GBM therapy...
  68. ncbi Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:2288-94. 2007
    ..We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status...
  69. pmc A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study
    H Ian Robins
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Neuro Oncol 4:109-14. 2002
    ..The significant myeloprotection afforded by thymidine may have particular relevance to polychemotherapeutic regimens...
  70. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  71. pmc A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 4:261-7. 2002
    ..Temozolomide was safe and effective in treating newly diagnosed GBM and AA before radiotherapy. This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies...
  72. ncbi Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
    ....
  73. ncbi Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
    Monica E Loghin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:7133-8. 2007
    ..The study was also intended to assess whether temozolomide affects the conversion of irinotecan to SN-38...
  74. ncbi Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
    John G Kuhn
    Pharmacotherapy Education and Research Center, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Clin Cancer Res 13:7401-6. 2007
    ..An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue...
  75. ncbi Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  76. pmc O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
    S Clifford Schold
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Neuro Oncol 6:28-32. 2004
    ..We conclude that a BG dose of 120 mg/m(2) given 6 h before an alkylating drug would be effective in suppressing AGT and possibly potentiating the cytotoxic effects of the drug...
  77. pmc A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    Neuro Oncol 10:569-76. 2008
    ..Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death...

Research Grants3

  1. PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM
    Michael Prados; Fiscal Year: 2003
    ..The aim of these treatment approaches is to increase disease-free and overall survival in children with brain tumors. ..
  2. NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
    Michael Prados; Fiscal Year: 2007
    ..The NABTC will treat patients using novel therapeutic agents with the ultimate goal to increase quality, and hopefully, overall survival in this patient population. ..
  3. NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
    Michael Prados; Fiscal Year: 2008
    ..The NABTC will treat patients using novel therapeutic agents with the ultimate goal to increase quality, and hopefully, overall survival in this patient population. ..